logo
CareCloud Delivers Growth and Strong Cash Flow in Q1 2025, Advances AI and Acquisition Strategy

CareCloud Delivers Growth and Strong Cash Flow in Q1 2025, Advances AI and Acquisition Strategy

Globe and Mail25-05-2025

SOMERSET, N.J., May 06, 2025 (GLOBE NEWSWIRE) -- CareCloud, Inc. (Nasdaq: CCLD, CCLDO), a leader in healthcare technology and generative AI solutions, today announced strong financial results for the three months ended March 31, 2025. CareCloud's strategic execution, AI-driven innovation, and disciplined financial management have fueled a transformational turnaround, positioning the Company for sustained profitability and long-term growth. Management will discuss these results and the Company's 2025 growth strategies in a live conference call today at 8:30 a.m. ET.
First Quarter 2025 Financial Highlights:
Revenue of $27.6 million, compared to $26.0 million in Q1 2024, an increase of 6% year-over-year
GAAP net income of $1.9 million, compared to a net loss of $241,000 in Q1 2024
Adjusted EBITDA of $5.6 million, compared to $3.7 million in Q1 2024, an increase of 52%
Adjusted net income of $2.3 million, or $0.05 per share
Cash balance of $6.8 million and net working capital of $11.7 million as of March 31, 2025
Recent Strategic Updates
AI Center of Excellence Launched: CareCloud launched its dedicated AI Center of Excellence, onboarding the first wave of over 50 AI professionals and aiming to scale to 500 AI specialists by fourth quarter 2025. The initiative is fully self-funded through operating cash flows.
Series A Preferred Stock Conversion Completed: Successfully converted 3.5 million Series A preferred shares into 26 million common shares, reducing the annual dividend commitment by approximately $7.7 million and strengthening cash flow and the capital structure.
Resumption of Preferred Dividends: Payments of preferred dividends resumed in February 2025.
Acquisition Strategy Reignited: Completed two strategic acquisitions in March and April 2025, with additional acquisition opportunities actively under evaluation.
Management Commentary:
"The launch of our AI Center of Excellence marks a pivotal moment in CareCloud's evolution," said A. Hadi Chaudhry, Co-CEO of CareCloud. "By building one of the largest dedicated healthcare AI teams globally, we believe we are creating real-world solutions to automate clinical workflows, optimize revenue cycle management, and improve patient outcomes. This initiative is intended to accelerate our operational efficiency as well as positioning CareCloud at the forefront of intelligent healthcare transformation — driving sustainable profitability and long-term growth for ourselves and the healthcare providers who use our services."
'After record profits and a successful turnaround in 2024, we are excited to announce continued momentum and strength as we enter 2025,' said Co-CEO Stephen Snyder. 'With two recent acquisitions and the launch of our AI Center of Excellence, CareCloud is not just responding to the market shift — we are intending to lead it.'
'We are pleased to announce our fourth consecutive quarter of positive GAAP net income and an increase in revenue and adjusted EBITDA year over year,' said Norman Roth, Interim CFO and Corporate Controller of CareCloud. 'We have resumed paying our Preferred Stock dividends monthly out of internally-generated free cash flow, while generating additional profits and cash flow to reinvest for future growth. To date we have declared six months of Preferred Stock dividends.'
Capital
On March 31, 2025, the Company had 984,530 shares of Series A Preferred Stock and 1,511,372 shares of non-convertible Series B Preferred Stock outstanding. As of March 31, 2025, the Series A and B shares both accrued dividends at the rate of 8.75% per annum, based on the $25.00 per share liquidation preference (equivalent to $2.1875 annually per share), and they are redeemable at the Company's option once the preferred stock dividends are brought current.
2025 Guidance: Poised for Growth
CareCloud is reconfirming its earnings guidance for 2025, expecting:
For the Fiscal Year Ending December 31, 2025
Forward-Looking Guidance
Revenue $111 – $114 million
Adjusted EBITDA $26 – $28 million
Net Income Per Share (EPS) $0.10 - $0.13
The Company continues to anticipate full year 2025 revenue of approximately $111 to $114 million. Revenue guidance is based on management's expectations regarding revenue from existing clients, organic growth in new client additions and anticipated number of small tuck-in acquisitions.
Adjusted EBITDA is expected to be $26 to $28 million for full year 2025 and reflects improvements from the Company's cost reduction efforts. EPS is expected to be $0.10 to $0.13 for full year 2025.
Conference Call Information
CareCloud management will host a conference call today at 8:30 a.m. Eastern Time to discuss the first three months of 2025 results. The live webcast of the conference call and related presentation slides can be accessed at ir.carecloud.com/events. An audio-only option is available by dialing 201-389-0920 and referencing 'CareCloud First Quarter 2025 Results Conference Call.' Investors who opt for audio-only will need to download the related slides at ir.carecloud.com/events.
A replay of the conference call and related presentation slides will be available approximately three hours after conclusion of the call at the same link. An audio-only option can also be accessed by dialing 412-317-6671 and providing the access code 13753440.
Use of Non-GAAP Financial Measures
In our earnings releases, prepared remarks, conference calls, slide presentations, and webcasts, we use and discuss non-GAAP financial measures, as defined by SEC Regulation G. The GAAP financial measure most directly comparable to each non-GAAP financial measure used or discussed, and a reconciliation of the differences between each non-GAAP financial measure and the comparable GAAP financial measure, are included in this press release after the condensed consolidated financial statements. Our earnings press releases containing such non-GAAP reconciliations can be found in the Investor Relations section of our web site at ir.carecloud.com.
Forward-Looking Statements
This press release contains various forward-looking statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements relate to anticipated future events, future results of operations or future financial performance. In some cases, you can identify forward-looking statements by terminology such as 'may,' 'might,' 'will,' 'shall,' 'should,' 'could,' 'intends,' 'expects,' 'plans,' 'goals,' 'projects,' 'anticipates,' 'believes,' 'seeks,' 'estimates,' 'forecasts,' 'predicts,' 'possible,' 'potential,' 'target,' or 'continue' or the negative of these terms or other comparable terminology.
Our operations involve risks and uncertainties, many of which are outside our control, and any one of which, or a combination of which, could materially affect our results of operations and whether the forward-looking statements ultimately prove to be correct. Forward-looking statements in this press release include, without limitation, statements reflecting management's expectations for future financial performance and operating expenditures, expected growth, profitability and business outlook, the impact of pandemics on our financial performance and business activities, and the expected results from the integration of our acquisitions.
These forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are only predictions, are uncertain and involve substantial known and unknown risks, uncertainties and other factors which may cause our (or our industry's) actual results, levels of activity or performance to be materially different from any future results, levels of activity or performance expressed or implied by these forward-looking statements. New risks and uncertainties emerge from time to time, and it is not possible for us to predict all of the risks and uncertainties that could have an impact on the forward-looking statements, including without limitation, risks and uncertainties relating to the Company's ability to manage growth, migrate newly acquired customers and retain new and existing customers, maintain cost-effective global operations, increase operational efficiency and reduce operating costs, predict and properly adjust to changes in reimbursement and other industry regulations and trends, retain the services of key personnel, develop new technologies, upgrade and adapt legacy and acquired technologies to work with evolving industry standards, compete with other companies' products and services competitive with ours, manage and keep our information systems secure and other important risks and uncertainties referenced and discussed under the heading titled 'Risk Factors' in the Company's filings with the Securities and Exchange Commission.
The statements in this press release are made as of the date of this press release, even if subsequently made available by the Company on its website or otherwise. The Company does not assume any obligations to update the forward-looking statements provided to reflect events that occur or circumstances that exist after the date on which they were made.
About CareCloud
CareCloud (Nasdaq: CCLD, CCLDO) brings disciplined innovation and generative AI solutions to the business of healthcare. Our suite of technology-enabled solutions helps clients increase financial and operational performance, streamline clinical workflows and improve the patient experience. More than 40,000 providers count on CareCloud to help them improve patient care while reducing administrative burdens and operating costs. Learn more about our products and services, including revenue cycle management (RCM), practice management (PM), electronic health records (EHR), artificial intelligence (AI), business intelligence (BI), patient experience management (PXM) and digital health, at carecloud.com.
Follow CareCloud on LinkedIn, X and Facebook.
For additional information, please visit our website at carecloud.com. To listen to video presentations by CareCloud's management team, read recent press releases and view the latest investor presentation, please visit ir.carecloud.com.
SOURCE CareCloud
CARECLOUD, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
($ in thousands, except share and per share amounts)
March 31, December 31,
2025 2024
(Unaudited)
ASSETS
Current assets:
Cash $ 6,805 $ 5,145
Accounts receivable - net 13,887 12,774
Contract asset 4,457 4,334
Inventory 609 574
Current assets - related party 16 16
Prepaid expenses and other current assets 2,843 1,957
Total current assets 28,617 24,800
Property and equipment - net 5,323 5,290
Operating lease right-of-use assets 3,097 3,133
Intangible assets - net 16,877 18,698
Goodwill 19,186 19,186
Other assets 456 507
TOTAL ASSETS $ 73,556 $ 71,614
LIABILITIES AND SHAREHOLDERS' EQUITY
Current liabilities:
Accounts payable $ 4,951 $ 4,565
Accrued compensation 2,865 1,817
Accrued expenses 5,002 4,951
Operating lease liability (current portion) 1,355 1,287
Deferred revenue (current portion) 1,297 1,212
Notes payable (current portion) 133 310
Contingent consideration (current portion) 47 -
Dividend payable 1,299 5,438
Total current liabilities 16,949 19,580
Notes payable 23 26
Contingent consideration 60 -
Operating lease liability 1,776 1,847
Deferred revenue 571 387
Total liabilities 19,379 21,840
COMMITMENTS AND CONTINGENCIES
SHAREHOLDERS' EQUITY:
Preferred stock, $0.001 par value - authorized 7,000,000 shares. Series A, issued and outstanding 984,530 and 4,526,231 shares at March 31, 2025 and December 31, 2024, respectively. Series B, issued and outstanding 1,511,372 shares at March 31, 2025 and December 31, 2024. 2 6
Common stock, $0.001 par value - authorized 85,000,000 shares. Issued 43,061,928 and 16,997,035 shares at March 31, 2025 and December 31, 2024, respectively. Outstanding 42,321,129 and 16,256,236 shares at March 31, 2025 and December 31, 2024, respectively 43 17
Additional paid-in capital 123,537 121,046
Accumulated deficit (64,682) (66,630)
Accumulated other comprehensive loss (4,061) (4,003)
Less: 740,799 common shares held in treasury, at cost at March 31, 2025 and December 31, 2024 (662) (662)
Total shareholders' equity 54,177 49,774
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY $ 73,556 $ 71,614
CARECLOUD, INC.
FOR THE THREE MONTHS ENDED MARCH 31, 2025 AND 2024
($ in thousands, except share and per share amounts)
Three Months Ended
March 31,
2025 2024*
NET REVENUE $ 27,632 $ 25,962
OPERATING EXPENSES:
Direct operating costs 15,464 15,177
Selling and marketing 1,131 1,770
General and administrative 4,332 3,721
Research and development 1,235 913
Depreciation and amortization 3,337 3,930
Restructuring costs 114 322
Total operating expenses 25,613 25,833
OPERATING INCOME 2,019 129
OTHER:
Interest income 42 27
Interest expense (58) (365)
Other (expense) income - net (14) 7
INCOME (LOSS) BEFORE PROVISION FOR INCOME TAXES 1,989 (202)
Income tax provision 41 39
NET INCOME (LOSS) $ 1,948 $ (241)
Preferred stock dividend 2,811 1,312
NET LOSS ATTRIBUTABLE TO COMMON SHAREHOLDERS $ (863) $ (1,553)
Net loss per common share: basic and diluted $ (0.04) $ (0.10)
Weighted-average common shares used to compute basic and diluted loss per share 23,813,943 16,014,309
* Restated to include the preferred stock dividends earned, but not declared, during the three months ended March 31, 2024.
CARECLOUD, INC.
FOR THE THREE MONTHS ENDED MARCH 31, 2025 AND 2024
($ in thousands)
2025 2024
OPERATING ACTIVITIES:
Net income (loss) $ 1,948 $ (241)
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Depreciation and amortization 3,407 4,020
Lease amortization 480 509
Deferred revenue 269 58
Provision for expected credit losses 70 37
Foreign exchange gain (1) (11)
Interest accretion 107 168
Stock-based compensation expense (benefit) 108 (708)
Changes in operating assets and liabilities:
Accounts receivable (1,183) (111)
Contract asset (105) (361)
Inventory (35) (15)
Other assets (908) -
Accounts payable and other liabilities 956 721
Net cash provided by operating activities 5,113 4,066
INVESTING ACTIVITIES:
Purchases of property and equipment (624) (298)
Capitalized software and other intangible assets (846) (1,570)
Initial payment for acquisition (40) -
Net cash used in investing activities (1,510) (1,868)
FINANCING ACTIVITIES:
Preferred stock dividends paid (1,730) -
Settlement of tax withholding obligations on stock issued to employees (21) (151)
Repayments of notes payable (181) (223)
Repayment of line of credit - (1,000)
Net cash used in financing activities (1,932) (1,374)
EFFECT OF EXCHANGE RATE CHANGES ON CASH (11) (17)
NET INCREASE IN CASH 1,660 807
CASH - Beginning of the period 5,145 3,331
CASH - End of the period $ 6,805 $ 4,138
SUPPLEMENTAL NONCASH INVESTING AND FINANCING ACTIVITIES:
Conversion of preferred stock and accrued dividends to common stock $ 2,435 $ -
Dividends declared, not paid $ 1,299 $ 5
Purchase of prepaid insurance with assumption of note $ - $ 96
Reclass of deposits for property and equipment placed in service $ - $ 296
SUPPLEMENTAL INFORMATION - Cash paid during the period for:
Income taxes $ 15 $ 6
Interest $ 18 $ 295
RECONCILIATION OF NON-GAAP FINANCIAL MEASURES
TO COMPARABLE GAAP MEASURES
The following is a reconciliation of the non-GAAP financial measures used by us to describe our financial results determined in accordance with accounting principles generally accepted in the United States of America ('GAAP'). An explanation of these measures is also included below under the heading 'Explanation of Non-GAAP Financial Measures.'
While management believes that these non-GAAP financial measures provide useful supplemental information to investors regarding the underlying performance of our business operations, investors are reminded to consider these non-GAAP measures in addition to, and not as a substitute for, financial performance measures prepared in accordance with GAAP. In addition, it should be noted that these non-GAAP financial measures may be different from non-GAAP measures used by other companies, and management may utilize other measures to illustrate performance in the future. Non-GAAP measures have limitations in that they do not reflect all of the amounts associated with our results of operations as determined in accordance with GAAP.
Adjusted EBITDA to GAAP Net Income (Loss)
Set forth below is a reconciliation of our 'adjusted EBITDA' to our GAAP net income (loss).
Non-GAAP Adjusted Operating Income to GAAP Operating Income
Set forth below is a reconciliation of our non-GAAP 'adjusted operating income' and non-GAAP 'adjusted operating margin' to our GAAP operating income and GAAP operating margin.
Three Months Ended March 31,
2025 2024
($ in thousands)
Net revenue $ 27,632 $ 25,962
GAAP net income (loss) 1,948 (241)
Provision for income taxes 41 39
Net interest expense 16 338
Other expense (income) - net 14 (7)
GAAP operating income 2,019 129
GAAP operating margin 7.3 % 0.5 %
Stock-based compensation expense (benefit) 108 (708)
Amortization of purchased intangible assets 89 840
Transaction and integration costs 12 12
Restructuring costs 114 322
Non-GAAP adjusted operating income $ 2,342 $ 595
Non-GAAP adjusted operating margin 8.5 % 2.3 %
Non-GAAP Adjusted Net Income to GAAP Net Income (Loss)
Set forth below is a reconciliation of our non-GAAP 'adjusted net income' and non-GAAP 'adjusted net income per share' to our GAAP net income (loss) and GAAP net loss per share.
Three Months Ended March 31,
2025 2024
($ in thousands)
GAAP net income (loss) $ 1,948 $ (241)
Foreign exchange loss (gain) / other expense 19 (5)
Stock-based compensation expense (benefit) 108 (708)
Amortization of purchased intangible assets 89 840
Transaction and integration costs 12 12
Restructuring costs 114 322
Non-GAAP adjusted net income $ 2,290 $ 220
End-of-period common shares 42,321,129 16,118,492
Non-GAAP adjusted net income per share $ 0.05 $ 0.01
For purposes of determining non-GAAP adjusted net income per share, we used the number of common shares outstanding as of March 31, 2025 and 2024.
Three Months Ended March 31,
2025 2024
GAAP net loss attributable to common shareholders, per share $ (0.04) $ (0.10)
Impact of preferred stock dividend 0.09 0.08
Net income (loss) per end-of-period share 0.05 (0.02)
Foreign exchange loss (gain) / other expense 0.00 0.00
Stock-based compensation expense (benefit) 0.00 (0.04)
Amortization of purchased intangible assets 0.00 0.05
Transaction and integration costs 0.00 0.00
Restructuring costs 0.00 0.02
Non-GAAP adjusted earnings per share $ 0.05 $ 0.01
Net cash provided by operating activities to free cash flow
Set forth below is a reconciliation of our non-GAAP 'free cash flow' to our GAAP net cash provided by operating activities.
Three Months Ended March 31,
2025 2024
($ in thousands)
Net cash provided by operating activities $ 5,113 $ 4,066
Purchases of property and equipment (624) (298)
Capitalized software and other intangible assets (846) (1,570)
Free cash flow $ 3,643 $ 2,198
Net cash used in investing activities 1 $ (1,510) $ (1,868)
Net cash used in financing activities $ (1,932) $ (1,374)
1 Net cash used in investing activities includes purchases of property and equipment and capitalized software and other intangible assets, which are also included in our computation of free cash flow.
Explanation of Non-GAAP Financial Measures
We report our financial results in accordance with accounting principles generally accepted in the United States of America, or GAAP. However, management believes that, in order to properly understand our short-term and long-term financial and operational trends, investors may wish to consider the impact of certain non-cash or non-recurring items, when used as a supplement to financial performance measures in accordance with GAAP. These items result from facts and circumstances that vary in frequency and impact on continuing operations. Management also uses results of operations before such items to evaluate the operating performance of CareCloud and compare it against past periods, make operating decisions, and serve as a basis for strategic planning. These non-GAAP financial measures provide management with additional means to understand and evaluate the operating results and trends in our ongoing business by eliminating certain non-cash expenses and other items that management believes might otherwise make comparisons of our ongoing business with prior periods more difficult, obscure trends in ongoing operations, or reduce management's ability to make useful forecasts. Management believes that these non-GAAP financial measures provide additional means of evaluating period-over-period operating performance. In addition, management understands that some investors and financial analysts find this information helpful in analyzing our financial and operational performance and comparing this performance to our peers and competitors.
Management uses adjusted EBITDA, adjusted operating income, adjusted operating margin, and non-GAAP adjusted net income to provide an understanding of aspects of operating results before the impact of investing and financing charges and income taxes. Adjusted EBITDA may be useful to an investor in evaluating our operating performance and liquidity because this measure excludes non-cash expenses as well as expenses pertaining to investing or financing transactions. Management defines 'adjusted EBITDA' as the sum of GAAP net income (loss) before provision for income taxes, net interest expense, foreign exchange loss (gain) / other expense, stock-based compensation expense (benefit), depreciation and amortization, transaction and integration costs, and restructuring costs.
Management defines 'non-GAAP adjusted operating income' as the sum of GAAP operating income before stock-based compensation expense (benefit), amortization of purchased intangible assets, transaction and integration costs, and restructuring costs, and 'non-GAAP adjusted operating margin' as non-GAAP adjusted operating income divided by net revenue.
Management defines 'non-GAAP adjusted net income' as the sum of GAAP net income (loss) before foreign exchange loss (gain) / other expense, stock-based compensation expense (benefit), amortization of purchased intangible assets, transaction and integration costs, and restructuring costs, and 'non-GAAP adjusted net income per share' as non-GAAP adjusted net income divided by common shares outstanding at the end of the period.
Management defines 'free cash flow' as the sum of net cash provided by operating activities less cash used for purchases of property and equipment and cash used to develop capitalized software and other intangible assets.
Management considers all of these non-GAAP financial measures to be important indicators of our operational strength and performance of our business and a good measure of our historical operating trends, in particular the extent to which ongoing operations impact our overall financial performance.
In addition to items routinely excluded from non-GAAP EBITDA, management excludes or adjusts each of the items identified below from the applicable non-GAAP financial measure referenced above for the reasons set forth with respect to that excluded item:
Foreign exchange loss (gain) / other expense. Other expense is excluded because foreign currency gains and losses and other non-operating expenses are expenditures that management does not consider part of ongoing operating results when assessing the performance of our business, and also because the total amount of the expense is partially outside of our control. Foreign currency gains and losses are based on global market factors which are unrelated to our performance during the period in which the gains and losses are recorded.
Stock-based compensation expense (benefit). Stock-based compensation expense (benefit) is excluded because this is primarily a non-cash expenditure that management does not consider part of ongoing operating results when assessing the performance of our business, and also because the total amount of the expenditure is partially outside of our control because it is based on factors such as stock price, volatility, and interest rates, which may be unrelated to our performance during the period in which the expenses are incurred. Stock-based compensation expense includes cash-settled awards based on changes in the stock price.
Amortization of purchased intangible assets. Purchased intangible assets are amortized over their estimated useful lives and generally cannot be changed or influenced by management after the acquisition. Accordingly, this item is not considered by management in making operating decisions. Management does not believe such charges accurately reflect the performance of our ongoing operations for the period in which such charges are recorded.
Transaction costs. Transaction costs are upfront costs related to acquisitions and related transactions, such as brokerage fees, pre-acquisition accounting costs and legal fees, and other upfront costs related to specific transactions. Management believes that such expenses do not have a direct correlation to future business operations, and therefore, these costs are not considered by management in making operating decisions. Management does not believe such charges accurately reflect the performance of our ongoing operations for the period in which such charges are incurred.
Integration costs. Integration costs are severance payments for certain employees relating to our acquisitions and exit costs related to terminating leases and other contractual agreements. Accordingly, management believes that such expenses do not have a direct correlation to future business operations, and therefore, these costs are not considered by management in making operating decisions. Management does not believe such charges accurately reflect the performance of our ongoing operations for the period in which such charges are incurred.
Restructuring costs. Restructuring costs primarily consist of severance and separation costs associated with the optimization of the Company's operations and profitability improvements. Management believes that such expenses do not have a direct correlation to future business operations, and therefore, these costs are not considered by management in making operating decisions. Management does not believe such charges accurately reflect the performance of our ongoing operations for the period in which such charges are incurred.
Free cash flow. Management believes that free cash flow, which measures our ability to generate additional cash from our business operations, is an important financial measure for use in evaluating the Company's financial performance. Free cash flow should be considered in addition to, rather than as a substitute for, consolidated net operating results as a measure of our performance and net cash provided by operating activities as a measure of our liquidity. Additionally, the Company's definition of free cash flow is limited, in that it does not represent residual cash flows available for discretionary expenditures, due to the fact that the measure does not deduct the payments required for debt service and other contractual obligations or payments made for business acquisitions. Therefore, we believe it is important to view free cash flow as a measure that provides supplemental information to our condensed consolidated statements of cash flows.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Family of Charleigh Pollock told decision coming soon on funding for her rare disease
Family of Charleigh Pollock told decision coming soon on funding for her rare disease

CTV News

time25 minutes ago

  • CTV News

Family of Charleigh Pollock told decision coming soon on funding for her rare disease

Charleigh Pollock poses on a field trip with her classmates on June 13, 2025. Charleigh Pollock is a nine-year-old girl who suffers from Batten disease, a rare neurodegenerative disorder that leads to the progressive loss of brain function. Charliegh was diagnosed at the tender age of three after she began suffering from relentless seizures. She was put on a drug call Brineura, which slowed the progression of the disease and stopped the seizures – until the B.C. government informed her medical team in February that she would no longer be covered. 'The last five months have been agonizing,' said Jori Fales, Charleigh's mother. 'It's on our minds every night and every morning, all day long.' The drugs is expensive, Fales said, costing $844,000 per year. Charleigh's team appealed the province's decision and the health minister stepped in, extending the treatments while the appeal process was ongoing. Fales said she's recently been told a decision is coming soon. 'We will hear the final decision before the 19th of June,' she said. Charleigh's mother fears the worst if the appeal doesn't go in her daughter's favour. 'Brineura is the only defence against this horrible disease, so if you take it away she will decline, lose more skills and will leave us,' she said. The province's Expensive Drug For Rare Disease Committee has been tasked with making the decision if Charleigh's treatment will be funded going forward. During that appeal process the committee asked the Canada Drug Agency to do an evidence review for Brineura. The findings of that report is giving Charleigh's mother hope. 'It says, 'insufficient data to establish discontinued criteria,'' said Fales. 'Without the appropriate data to help inform stopping the drug, the discontinuation should truly be a clinical decision made with the health-care team and the families impacted with this disease.' Charleigh's medical team is in full support of the nine-year-old's continued Brineura treatment. June 19 – the same day the family has been told they will receive the province's decision – is also the next scheduled infusion treatment. If the decision doesn't go in Charleigh's favour, that will be her last treatment with the drug that her mother says is keeping her alive. 'Then we start preparing ourselves for the days ahead,' said Fales.

Previewing Q2 Earnings Expectations
Previewing Q2 Earnings Expectations

Globe and Mail

time33 minutes ago

  • Globe and Mail

Previewing Q2 Earnings Expectations

The expectation is for Q2 earnings to increase by +5.1% from the same period last year on +3.8% higher revenues. This will be a material deceleration from the +11.9% earnings growth in Q1 on +3.6% revenue growth. In the unlikely event that actual Q2 earnings growth for the S&P 500 index turns out to be +5.1%, as currently expected, this will be the lowest earnings growth pace for the index since the +4.3% growth rate in 2023 Q3. We have been regularly flagging in recent weeks that 2025 Q2 earnings estimates have been steadily decreasing, as shown in the chart below. The magnitude of cuts to 2025 Q2 estimates since the start of the period is larger and more widespread compared to what we have become accustomed to seeing in the post-COVID period. Since the start of April, Q2 estimates have declined for 14 of the 16 Zacks sectors (Aerospace and Utilities are the only sectors whose estimates have increased), with the largest cuts to Conglomerates, Autos, Transportation, Energy, Basic Materials, and Construction sectors. Estimates for the Tech and Finance sectors, the largest earnings contributors to the S&P 500 index, accounting for more than 50% of all index earnings, have also been cut since the quarter got underway. But as we have been pointing out in recent weeks, the revisions trend for the Tech sector has notably stabilized in recent weeks, which you can see in the chart below. We see this same trend at play in annual estimates as well. The chart below shows the Tech sector's evolving earnings expectations for full-year 2025 A likely explanation for this stabilization in the revisions trend is the easing of tariff uncertainty after the more punitive version of the tariff regime was delayed. Analysts started revising their estimates lower in the immediate aftermath of the early April tariff announcements, but appear to have since concluded that those punitive tariff levels are unlikely to get levied, helping stabilize the revisions trend. The chart below shows current Q2 earnings and revenue growth expectations in the context of the preceding four quarters and the coming three quarters. The chart below shows the overall earnings picture on a calendar-year basis. In terms of S&P 500 index 'EPS', these growth rates approximate to $254.04 for 2025 and $287 for 2026. The chart below shows how these calendar year 2025 earnings growth expectations have evolved since the start of Q2. As you can see below, estimates fell sharply at the beginning of the quarter, which coincided with the tariff announcements, but have notably stabilized over the last four to six weeks. Key Earnings Reports This week The Q2 earnings season will really get going when the big banks come out with their June-quarter results in about a month. But we will have officially counted almost two dozen quarterly reports from S&P 500 members by then. All of those reports will be from companies with fiscal quarters ending in May, which we and other research organizations count as part of the June-quarter tally. We have seen such fiscal May-quarter results from four S&P 500 members, including last Wednesday's strong release from Oracle ORCL. We have another six S&P 500 members scheduled to report results this week, including Accenture ACN, Lennar LEN, and others. Oracle shares were up significantly following the beat-and-raise quarterly release, which came after two consecutive quarterly reports that market participants had found disappointing. Oracle's cloud growth appears to have finally arrived, with fiscal 2026 cloud revenues expected to grow by +40%, up from the fiscal 2025 growth rate of +24% (Oracle's fiscal year ends in May). As noted earlier, the stock has spiked on the earnings release and is now up +29.3% this year, handily outperforming the S&P 500 index (up +2.1%) and the Zacks Tech sector (up +2.5%). Shares of IT consulting firm Accenture have been under pressure lately, reflecting a challenging operating environment for its end-markets. The stock is down -11.4% this year, which compares to a +2.1% gain for the S&P 500 index and a +2.5% gain for the Zacks Tech sector. The issues in the Accenture story, in a generalized qualitative sense, pertain to the negative effects on corporate IT budgets of the ongoing tariff uncertainty and the deflationary effects of AI-driven operating efficiencies. One could argue that Accenture's scale lends its results considerable stability, particularly in comparison to other peers like India-based Infosys, TCS, and Wipro. But these macro headwinds nevertheless limit the stock's near-term upside potential. The company is scheduled to report results on June 20 th, with estimates essentially unchanged over the last two months. Lennar, the homebuilder, is scheduled to report results after the market's close on Monday, June 16 th. The homebuilder is expected to bring in $1.97 per share in earnings on $8.24 billion in revenues, representing year-over-year changes of -41.7% and -5.97%, respectively. This is a challenging environment for Lennar and other homebuilders, with demand hindered by affordability concerns and elevated mortgage rates. The stock was down after each of the last five quarterly releases and has lost roughly a fifth of its value this year (down -20.3%), which compares to the Zacks Construction sector's -1.9% decline and the S&P 500 index's +2.2% gain. Q2 Earnings Season Scorecard As noted earlier, we have already seen fiscal May-quarter results from four S&P 500 members, which we include in our Q2 tally. Total earnings for these four index members that have reported results are up +4.7% from the same period last year on +8.6% revenue gains, with 75% of the companies beating EPS estimates and all beating revenue estimates. The comparison charts below put the Q2 earnings and revenue growth rates for these index members in a historical context. The comparison charts below put the Q2 EPS and revenue beats percentages in a historical context. We are not drawing any conclusions from these results, given the small sample size at this stage. But we nevertheless wanted to put these early results in a historical context. 7 Best Stocks for the Next 30 Days Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers "Most Likely for Early Price Pops." Since 1988, the full list has beaten the market more than 2X over with an average gain of +23.5% per year. So be sure to give these hand picked 7 your immediate attention. See them now >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Accenture PLC (ACN): Free Stock Analysis Report Oracle Corporation (ORCL): Free Stock Analysis Report Lennar Corporation (LEN): Free Stock Analysis Report This article originally published on Zacks Investment Research (

Trump clears path for Nippon Steel investment in US Steel, so long as it fits the government's terms
Trump clears path for Nippon Steel investment in US Steel, so long as it fits the government's terms

CTV News

time36 minutes ago

  • CTV News

Trump clears path for Nippon Steel investment in US Steel, so long as it fits the government's terms

WASHINGTON — U.S. President Donald Trump on Friday signed an executive order paving the way for a Nippon Steel investment in U.S. Steel, so long as the Japanese company complies with a 'national security agreement' submitted by the federal government. Trump's order didn't detail the terms of the national security agreement. But U.S. Steel and Nippon Steel said in a joint statement that the agreement stipulates that approximately US$11 billion in new investments will be made by 2028 and includes giving the U.S. government a 'golden share' — essentially veto power to ensure the country's national security interests are protected. 'We thank President Trump and his Administration for their bold leadership and strong support for our historic partnership,' the two companies said. 'This partnership will bring a massive investment that will support our communities and families for generations to come. We look forward to putting our commitments into action to make American steelmaking and manufacturing great again.' The companies have completed a U.S. Department of Justice review and received all necessary regulatory approvals, the statement said. 'The partnership is expected to be finalized promptly,' the statement said. The companies offered few details on how the golden share would work and what investments would be made. Trump said Thursday that he would as president have 'total control' of what U.S. Steel did as part of the investment. Trump said then that the deal would preserve '51 per cent ownership by Americans.' The Japan-based steelmaker had been offering nearly $15 billion to purchase the Pittsburgh-based U.S. Steel in a merger that had been delayed on national security concerns starting during Joe Biden's presidency. Trump opposed the purchase while campaigning for the White House, yet he expressed optimism in working out an arrangement once in office. 'We have a golden share, which I control,' said Trump, although it was unclear what he meant by suggesting that the federal government would determine what U.S. Steel does as a company. Trump added that he was 'a little concerned' about what presidents other than him would do with their golden share, 'but that gives you total control.' Still, Nippon Steel has never said it was backing off its bid to buy and control U.S. Steel as a wholly owned subsidiary. The proposed merger had been under review by the Committee on Foreign Investment in the United States, or CFIUS, during the Trump and Biden administrations. The order signed Friday by Trump said the CFIUS review provided 'credible evidence' that Nippon Steel 'might take action that threatens to impair the national security of the United States,' but such risks might be 'adequately mitigated' by approving the proposed national security agreement. The order doesn't detail the perceived national security risk and only provides a timeline for the national security agreement. The White House declined to provide details on the terms of the agreement. The order said the draft agreement was submitted to U.S. Steel and Nippon Steel on Friday. The two companies must successfully execute the agreement as decided by the Treasury Department and other federal agencies that are part CFIUS by the closing date of the transaction. Trump reserves the authority to issue further actions regarding the investment as part of the order he signed on Friday. Associated Press writer Marc Levy in Harrisburg, Pa., contributed to this report Josh Boak, The Associated Press

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store